Retatrutide: What Does the 24.2% Weight-Loss Result Mean?
Read the 338-person trial without confusing an average result with a promise.
Read article →Related research productsRetatrutide →
Understand the study
Published research explained
Start with a question: how was the experiment done, what do the results mean, and which research material is relevant?
12 study explanations · Choose a topic to find a study.
Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers
What 2,539 participants, three study groups and a placebo comparison tell us.
Read article →Related research productsTirzepatide →
CJC-1295 With DAC: What Does a Long Half-Life Tell Us?
Understand the hormone measurements before making claims about muscle or recovery.
Read article →Related research productsCJC-1295 with DAC →
BPC-157 and TB-500: Did the Combination Help Rat Tendons More?
A small rat study shows why “combined” does not automatically mean “better.”
Read article →
Tirzepatide and Body Composition: Was the Lost Weight All Fat?
A scan substudy separates body weight, fat mass and lean mass.
Read article →Related research productsTirzepatide →
MOTS-c and Cold: How Did the Mice Keep Warm?
Understand brown fat and heat production without turning a mouse experiment into a weight-loss promise.
Read article →Related research productsMOTS-c →
LL-37 Wound Trial: Why Did the Overall and Subgroup Results Differ?
Learn how to read a 148-person trial without selecting only its most positive finding.
Read article →Related research productsLL-37 →
SS-31 in Aged Muscle: Better Energy Supply or More Mitochondria?
Separate the amount of cellular machinery from how well it works.
Read article →Related research productsSS-31 / Elamipretide →
KPV and Colitis: What Was Inside the Nanodrug?
Follow the ingredients, comparison groups and measurements in a mouse study.
Read article →Related research productsKPV →
Oxytocin and Appetite: Why Eating Less Did Not Mean Weight Loss
Read a test-meal result alongside the trial’s main eight-week weight result.
Read article →Related research productsOxytocin Acetate →
Thymosin Beta-4 and Dry Eye: Why the Main Result Matters
Understand eye-surface staining, discomfort scores and the difference between main and secondary outcomes.
Read article →Related research productsTB-500 / Thymosin β4 Acetate →
Afamelanotide: What Does “Pain-Free Sunlight Time” Mean?
Separate a rare-disease trial from ordinary tanning or sun-protection claims.
Read article →Related research productsMelanotan I / Afamelanotide →
Four terms that help you read a study
Control group
A comparison group that helps identify what contributed to an observed change.
Average
A summary of a group, not a promise that every participant had the same result.
Primary outcome
The main measure chosen before the trial; other findings do not replace that result.
Animal study
Useful for investigating mechanisms, but not direct evidence of an effect in people.
This is a research-reading library. Clinical preparations, experimental systems and catalog materials need separate confirmation.
Discuss material requirements →Browse research products →More related research explanations
Reading paths updated 5 October 2026
New research readings: find the result behind the headline
These summaries explain what researchers measured, who or what was studied, and which comparison produced the reported result. Read the full guide before connecting a finding to a product.
Was this tested in people, animals or cells?
A result in cultured cells or an animal model is useful research evidence. It does not establish the same effect in people. Each summary identifies the model.
What does the reported number actually measure?
Check the endpoint, control group and study duration. A change in a biomarker and a change in body weight answer different questions.
GHK-Cu and collagen: what the cell experiment actually showed
GHK-Cu is often discussed as a collagen-related peptide. The useful question is more specific: did researchers measure collagen directly, and in what kind of experiment? An early fibroblast study offers a clear answer, without establishing a skin-care outcome in people.
Read the explanation →MOTS-c and exercise: natural increases are not supplementation results
MOTS-c is a short peptide encoded within mitochondrial DNA. A widely discussed exercise paper contains two different kinds of evidence: researchers administered MOTS-c to mice, and they measured naturally produced MOTS-c after exercise in humans. Keeping those parts separate makes the findings much easier to understand.
Read the explanation →Retatrutide in type 2 diabetes: reading the 24-week glucose results
Retatrutide has been studied for both weight and blood-glucose outcomes. Those are related but different endpoints. A phase 2 trial in people with type 2 diabetes is useful because it reports each outcome with its own time point and comparison group.
Read the explanation →CagriSema in diabetes: what the 68-week combination trial tells us
CagriSema is a combination of cagrilintide and semaglutide. A result for that combination cannot be assigned to cagrilintide alone. REDEFINE 2 helps show both the benefits observed and the limits of what a combination trial can answer.
Read the explanation →KPV delivery research: what “12,000-fold lower” really refers to
A headline about a much lower peptide concentration can sound like proof that the peptide itself became stronger. In a KPV study, however, the delivery system was central to the result. The researchers were studying where and how the material reached its target.
Read the explanation →Ipamorelin selectivity: what the original animal study measured
“Selective” sounds reassuring, but it describes a particular experimental comparison. The original ipamorelin pharmacology paper tested growth-hormone release and several other hormones in laboratory and animal models. It did not establish that every possible effect or risk was absent.
Read the explanation →Found a relevant material? Send its name, required quantity and the documents you need. Availability and batch records are confirmed individually.